Merck & Co., Inc.
MRK Healthcare Drug Manufacturers - General NYSE
$115.79
$-0.28 (-0.24%)
Open: $115.16 | High: $116.36 | Low: $113.82 | Prev Close: $116.07
Market Cap: $286.28B
Volume: 6.6M | Avg: 13.2M
Last updated: March 09, 2026 at 02:03 AMInvestment Rating
Buy
Overall Score: 80/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 630
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 15.95 |
| P/B Ratio | 5.48 |
| P/S Ratio | 4.40 |
| EPS | $7.26 |
| Beta | 0.26 |
| Shares Outstanding | 2.47B |
| 52-Week High | $125.14 |
| 52-Week Low | $73.31 |
| SMA 50 | $113.88 |
| SMA 200 | $92.71 |
| Dividend Yield | 2.83% |
| Annual Dividend | $3.28 |
| Next Earnings | April 30, 2026 01:30 PM ET |
Financial Ratios
| Gross Margin | 81.5% |
| Operating Margin | 41.2% |
| Net Margin | 28.1% |
| ROE | 36.2% |
| ROA | 13.3% |
| Debt/Equity | 0.96 |
| Current Ratio | 1.54 |
| Quick Ratio | 1.30 |
Balance Sheet
| Total Assets | $136.87B |
| Total Liabilities | $84.20B |
| Total Equity | $52.61B |
|
|
|
| Cash | $14.56B |
| Total Debt | $50.53B |
| Net Debt | $35.97B |
Income Statement
| Revenue | $65.01B |
| Gross Profit | $52.98B |
| Operating Income | $26.78B |
| Net Income | $18.25B |
|
|
|
| EBITDA | $25.36B |
| Revenue/Share | $26.11 |
Cash Flow
| Operating CF | $16.47B |
| CapEx | $4.11B |
| Free Cash Flow | $12.36B |
|
|
|
| Book Value/Share | $21.15 |
| Tangible Book/Share | $1.77 |
| Equity/Share | $21.13 |
Technical Indicators
| RSI (14) | 29.59 Oversold |
| MACD |
1.26
Signal: 2.53
|
| Volatility | 29.72% |
| Trading Signal | Oversold |
Performance & Returns
| 1 Year | +49.93% |
| Sharpe Ratio | 1.75 Good |
| Volatility (Ann.) | 27.39% Moderate |
| MRK (1Y) | +49.93% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | +36.9% |
Sector Comparison (Healthcare)
| Metric | MRK | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 15.95 | 27.88 | 19% |
| P/B Ratio | 5.48 | -19.63 | 70% |
| ROE (%) | 36.19% | -9.98% | 85% |
| Net Margin (%) | 28.08% | 8.96% | 87% |
| Stock Score | 630 | 542.0 | 94% |
| 1Y Return (%) | +49.93 % | +7.32 % | 92% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRK | $115.79 | $118.37 | $119.64 | $120.57 | $113.83 | $92.70 | 29.59 | 1.26 | 29.72% | 1772124 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the MRK stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| MRK | Merck & Co., Inc. $MRK is Arrowstreet Capital Limited Partnership’s 10th Largest Position | Neutral | defenseworld.net | Read More |
| MRK | Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150 | Neutral | 247wallst.com | Read More |
| MRK | Capital Group Private Client Services Inc. Lowers Stock Position in Merck & Co., Inc. $MRK | Neutral | defenseworld.net | Read More |
| MRK | Capital International Inc. CA Cuts Position in Merck & Co., Inc. $MRK | Neutral | defenseworld.net | Read More |
| MRK | Harbor Health Care ETF Q4 2025 Portfolio Review | Neutral | seekingalpha.com | Read More |
Recent Insider Trading
No recent insider trading data available for MRK
Company Information
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
| CEO | Robert Davis |
| Employees | 73000 |
| Country | US |
| IPO Date | 1978-01-13 |
| Exchange | NYSE |
| Website | https://www.merck.com |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Similar Stocks (Healthcare - Drug Manufacturers - General)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category